ScholarWorks@Korea University: Seo, Jae Hong

Detailed Information

Seo, Jae Hong (서재홍)

Graduate School (Department of Biomedical Sciences)

Research Area: New Drug Development in TNBC, HSP90 inhibitor, Cancer Stem Cell, 삼중음성유방암에서 신약개발연구, HSP90 inhibitor, 암줄기세포

Tel 02-2626-3059
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Breast cancer:13||Cancer stem cells:7||breast cancer:6||Metastasis:6||Metaanalysis:5||Triplenegative breast cancer:5||HER2positive breast cancer:5||Trastuzumab resistance:4||p95HER2:4||HER2:4||docetaxel:4||Chemotherapy:4||Metastatic breast cancer:4||Apoptosis:4||Disulfiram:3||Human epidermal growth factor receptor 2:3||Heat shock protein 90:3||Docetaxel:3||EMT:3||Cterminal HSP90 inhibitor:3||Breast neoplasms:3||STAT3:3||Deguelin:3||Pluronic nanoparticles:3||Adjuvant chemotherapy:2||TAC chemotherapy:2||Breast cancer risk:2||Pegylated GCSF:2||ALDH1A1:2||Korea:2||Drug repurposing:2||Breast cancer stem cells:2||Doxorubicin:2||HSP90:2||Pancreatic neoplasms:2||Mammosphere:2||Lung cancer:2||chemotherapy:2||ALDH1:2||Neutropenia:2||Taxanes:2||Korean:2||cancer stem cells:2||Visible:1||prognostic indicator:1||recurrence:1||Antitumor:1||Macromolecules:1||metastasis:1||estrogen receptor:1||USP34:1||Autophagy:1||safety:1||Wild type:1||Solgel transition:1||Neoplasm metastasis:1||MVAC protocol:1||Secondline chemotherapy:1||Prognostic factors:1||elderly patients:1||Nonsmallcell lung cancer:1||Metastatic burden:1||dose reduction:1||Anthracyclines:1||FOLFIRI:1||Bevacizumab:1||Tyrosine kinase inhibitors:1||5FU:1||refractory colon cancer:1||509 C/T polymorphism:1||Epirubicin:1||Anthracycline:1||Preoperative:1||IGFBP3:1||APCmutated:1||betacatenin:1||molecular subtype:1||DHP107:1||HER2negative:1||FAK:1||Cyclophosphamide:1||Hypoxia Inducible Factor1a:1||Small molecules:1||insulin receptor substrate 1:1||apoptosis:1||Flubendazole:1||elderly:1||Mammary gland development:1||H1299 and H460 human nonsmall cell lung cancer cell lines:1||Caveolin 1:1||Febrile neutropenia:1||rapamycin:1||Salinomycin:1||Intravenous access:1||Cisplatin failure:1||biologically aggressive:1||Epithelial to mesenchymal transition:1||Transdifferentiation:1||CD8(+) T cell:1||secondline chemotherapy:1||Twin births:1||toxicity:1||Janus kinase 3:1||Salvage treatment:1||mitomycin:1||Chemotherapy, second line:1||Adjuvant therapy:1||Aromatase inhibitor:1||Korean population:1||haplotypes:1||lung cancer:1||IFN?:1||isolated locoregional recurrence:1||Gastric cancer:1||Triple negative breast cancer:1||MDR1:1||Nearinfrared:1||Pegfilgrastim:1||Prognosis:1||obstructive lung disease:1||In situ gel:1||flubendazole:1||triplenegative breast cancer:1||prodrug:1||comorbidity:1||Sternness:1||Angiogenesis:1||Prognostic factor:1||stemness factor:1||resistance:1||NSCLC:1||Nonsmall cell lung carcinoma:1||Nanoparticles/polymer mixture:1||Complication:1||Sarcoidosis:1||Prognostic marker:1||metastatic lymphatics:1||primary tumor targeting:1||Foxp3(+) Treg:1||Urothelial cell carcinoma:1||Nonsmallcell lung carcinoma:1||methylation:1||Stage:1||Overall survival:1||ACEI/ARB:1||Vinorelbine:1||capecitabine:1||Epidermal growth factor receptor mutation:1||Concomitant chemoradiation:1||Prognostic model:1||Transforming growth factor:1||Activin receptorlike kinase (ALK):1||SNP:1||PPARgamma ligand:1||NO donor:1||BclXL:1||single nucleotide polymorphisms:1||Akt:1||TNF?:1||disease free survival:1||Doxazosin:1||Abemaciclib:1||Midinfrared:1||HIF1 alpha:1||combination therapy:1||nonsmall cell lung carcinoma:1||epidermal growth factor receptor:1||secondline treatment:1||Eribulin:1||Anoikis:1||Calpain:1||Carcinoma:1||Small cell lung cancer:1||EML4ALK:1||Pluronics:1||Extravasation:1||Urothelial carcinoma:1||YKL40:1||lymphatic tracking:1||TGF beta:1||Aged:1||Bone morphogenetic protein2:1||FOLFOX:1||Nasopharyngeal carcinoma:1||Sensitive:1||Eat shock protein 90:1||5Fluorouracil:1||metastatic breast cancer:1||firstline:1||Ebastine:1||Diagnostic bioimaging:1||Filgrastim:1||Advanced lung cancer:1||Phase transition:1||L80:1||photodynamic therapy:1||Singleincision technique:1||Phase IV clinical trial:1||Solutol:1||cancer therapy:1||Skeletalrelated event:1||Epidermal growth factor receptor:1||Firstline chemotherapy:1||HER3:1||cancer stem cell:1||ErbB2:1||Effective cancer therapy:1||The Microprocessor complex:1||Gemcitabine and carboplatin:1||Drug therapy:1||peripheral neuropathy:1||Polymorphism:1||VEGF:1||tumor protein p53 (TP53):1||TGF?1:1||EGFR:1||HER2Positive breast cancer:1||NCT547:1||lung function:1||nonalcoholic fatty liver disease:1||prognosis:1||Pluronic/heparin nanoparticles:1||Polymeric micelle paclitaxel:1||Complications:1||Autophagy flux:1||Autophagy inhibitor:1||Safety:1||Smad4:1||Pluronic F68:1||Exenatide:1||neuregulin:1||Targeting enhancement:1||Subcutaneous port:1||Cell cycle:1||Biliary tract cancer:1||Elderly:1||prognostic model:1||Solid cancer:1||Varicella zoster virus:1||cyclin B1:1||Reninangiotensin system:1||paclitaxel:1||936 C/T polymorphism:1||Mesenchymal stem cells (MSCs):1||NF kappa B:1||transforming growth factorbeta:1||Prognostic biomarker:1||Salvage therapy:1||Binary prodrug:1||MonarchE:1||Indazole:1||Fluorescent probe:1||Inflammation:1||prognostic factors:1||Implantable venous access port:1||Losartan:1||multilayer nanoparticles:1||Bone metastases:1||Ultrasoundinduced:1||Cancer patient:1||Secondline:1||Mitosis:1||temperatureinduced phase transition:1||Transforming growth factor beta:1||early breast cancer:1||Pancreatic adenocarcinoma:1||Gemcitabine:1||Capecitabine:1||febrile neutropenia:1||Haplotypes:1||Lung adenocarcinoma:1||leucovorin:1||Costeffectiveness:1||cMyc:1||ADI:1||Trastuzumabresistant breast cancer:1||Oxaliplatin:1||cMET:1||Drug accessibility:1||HVH2930:1||Cremophor ELfree:1||GenexolPM:1||Axillary vein:1||Ulmus davidiana Nakai (UDN):1||AGTR1:1||nonsmall cell lung cancer:1||Sustained delivery:1||Type 2 diabetes mellitus:1||Peptide vaccine:1||Cancer stem cell:1||Spontaneous tumor:1||Infection:1||Positronemission tomography:1||Aurora kinase B:1||RASSF1A:1||gastric cancer:1||Dose delay:1||TGFbeta 1:1||Retrospective analysis:1||Esophageal squamous cell carcinoma:1||Human breast epithelial cells:1||Smad3:1||Differentiation:1||Tamoxifen:1||tamoxifen:1||oral paclitaxel:1||betaescin:1||Patientreported outcome:1||Quality of life:1||trastuzumab resistance:1||

RSS_1.0 RSS_2.0 ATOM_1.0

145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE